Several new studies presented at the American Urological Association's (AUA) 104th Annual Scientific Meeting suggest that the use of statins - commonly prescribed to lower cholesterol - may benefit men with prostate cancer, erectile dysfunction or lower urinary tract symptoms (LUTS).
Several key research studies highlighting these benefits will be presented during a special panel for the media on Monday, April 27 from 9 to 10:30 a.m. during the 104th Annual Scientific Meeting of the American Urological Association (AUA).
The following study findings will be discussed by authors during the panel press conference:
Abstract 576: Is statin use associated with prostate cancer aggressiveness? Use of statins may be associated with more favorable pathological features at radical prostatectomy, including adverse tumor features and lower risk of positive surgical margins.
Abstract 1598: Statin medication use and the risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database Statin use may be associated with a reduction in the risk of biochemical recurrence following prostatectomy.
Abstract 574: Associations between statin use and prostate-specific antigen levels and prostate cancer diagnosis. Statin use may be associated with a decreased risk of prostate biopsy, prostate cancer and exceeding age-specific prostate-specific antigen thresholds. Statin use may also prevent the development of prostate cancer.